Tumor Suppressor 101F6 and Ascorbate Synergistically and Selectively Inhibit Non–Small Cell Lung Cancer Growth by Caspase-Independent Apoptosis and Autophagy
Open Access
- 1 July 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (13), 6293-6303
- https://doi.org/10.1158/0008-5472.can-06-3884
Abstract
101F6 is a candidate tumor suppressor gene harbored on chromosome 3p21.3, a region with frequent and early allele loss and genetic alterations in many human cancers. We previously showed that enforced expression of wild-type 101F6 by adenoviral vector–mediated gene transfer significantly inhibited tumor cell growth in 3p21.3-deficient non–small cell lung cancer (NSCLC) cells in vitro and in vivo. The molecular mechanism of 101F6-mediated tumor suppression is largely unknown. A computer-aided structural and functional model predicts the 101F6 protein to be a member of the cytochrome b561 protein family that is involved in the regeneration of the antioxidant ascorbate. 101F6 protein is expressed in normal lung bronchial epithelial cells and fibroblasts but is lost in most lung cancers. Treatment with 101F6 nanoparticle–mediated gene transfer in combination with a subpharmacologic dose (200–500 μmol/L) of ascorbate synergistically and selectively inhibited lung cancer cell growth in vitro. Systemic injection of 101F6 nanoparticles plus the i.p. injection of ascorbate synergistically inhibited both tumor formation and growth in human NSCLC H322 orthotopic lung cancer mouse models (P < 0.001). Furthermore, exogenous expression of 101F6 enhanced intracellular uptake of ascorbate, leading to an accumulation of cytotoxic H2O2 and a synergistic killing of tumor cells through caspase-independent apoptotic and autophagic pathways. The antitumor synergism showed by the combination treatment with systemic administration of 101F6 nanoparticles and ascorbate on lung cancer offers an attractive therapeutic strategy for future clinical trials in cancer prevention and treatment. [Cancer Res 2007;67(13):6293–303]This publication has 33 references indexed in Scilit:
- Intravenously administered vitamin C as cancer therapy: three casesCMAJ : Canadian Medical Association Journal, 2006
- The role of autophagy in cancer development and response to therapyNature Reviews Cancer, 2005
- Inhibition of the DNA-Dependent Protein Kinase Catalytic Subunit Radiosensitizes Malignant Glioma Cells by Inducing AutophagyCancer Research, 2005
- Cell Death Independent of Caspases: A ReviewClinical Cancer Research, 2005
- Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivoCancer Gene Therapy, 2004
- Vitamin C in Alternative Cancer Treatment: Historical BackgroundIntegrative Cancer Therapies, 2003
- Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancersOncogene, 2002
- Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders?Human Molecular Genetics, 2001
- Anticancer Therapy by Overexpression of Superoxide DismutaseAntioxidants and Redox Signaling, 2001
- Dissection of Autophagosome Formation Using Apg5-Deficient Mouse Embryonic Stem CellsThe Journal of cell biology, 2001